IDH2 and central nervous system cancer: The high incidence of IDH-driver mutations in gliomas, combined with the lack of appropriate in vitro cell cultures has resulted in numerous studies in which effects of IDH-mutants are tested in cell models utilizing overexpression of mutated IDH.